MoonLake Immunotherapeutics (MLTX) Gains from Investment Securities (2021 - 2026)

MoonLake Immunotherapeutics' Gains from Investment Securities history runs 6 years deep, the most recent figure standing at -$422000.0 for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 240.32% year-over-year to -$422000.0; the TTM figure through Mar 2026 stood at $289000.0 (up 180.58% YoY), while the FY2025 annual figure was $587000.0, up 158.59% from the prior year.
• Gains from Investment Securities was -$422000.0 for Q1 2026 at MoonLake Immunotherapeutics, down from $587000.0 in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $3.7 million in Q4 2023 to a low of -$1.2 million in Q3 2025.
• Historically, Gains from Investment Securities has averaged $318928.9 across 5 years, with a median of $1277.0 in 2022.
• Biggest YoY gain for Gains from Investment Securities was 769.47% in 2023; the steepest drop was 1902.28% in 2023.
• A 5-year view of Gains from Investment Securities shows it stood at $429501.0 in 2022, then surged by 769.47% to $3.7 million in 2023, then tumbled by 93.92% to $227000.0 in 2024, then soared by 158.59% to $587000.0 in 2025, then plunged by 171.89% to -$422000.0 in 2026.
• The last three Gains from Investment Securities figures came in at -$422000.0 (Q1 2026), $587000.0 (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.